Minimally Invasive Versus open AbdominoThoracic Esophagectomy for esophageal carcinoma (MIVATE) - study protocol for a randomized controlled trial DRKS00016773.

Circular stapled anastomosis Comprehensive complication index Enhanced recovery after surgery Esophageal cancer Expertise-based Fast track Ivor-Lewis esophagectomy Linear stapled anastomosis Minimally invasive esophagectomy Randomized controlled trial

Journal

Trials
ISSN: 1745-6215
Titre abrégé: Trials
Pays: England
ID NLM: 101263253

Informations de publication

Date de publication:
11 Jan 2021
Historique:
received: 10 05 2020
accepted: 11 12 2020
entrez: 12 1 2021
pubmed: 13 1 2021
medline: 22 6 2021
Statut: epublish

Résumé

The only curative treatment for most esophageal cancers is radical esophagectomy. Minimally invasive esophagectomy (MIE) aims to reduce postoperative morbidity, but is not yet widely established. Linear stapled anastomosis is a promising technique for MIE because it is quite feasible even without robotic assistance. The aim of the present study is to compare total MIE with linear stapled anastomosis to open esophagectomy (OE) with circular stapled anastomosis with special regard to postoperative morbidity in an expertise-based randomized controlled trial (RCT). This superiority RCT compares MIE with linear stapled anastomosis (intervention) to OE with circular stapled anastomosis (control) for Ivor-Lewis esophagectomy. It was initiated in February 2019, and recruitment is expected to last for 3 years. For inclusion, patients must be 18 years of age or more with a resectable primary malignancy in the distal esophagus. Participants with tumor localizations above the azygos vein, metastasis, or infiltration into adjacent tissue will be excluded. In an expertise-based approach, the allocated treatment will only be carried out by the single most experienced surgeon of the surgical center for each respective technique. The sample size was calculated with 20 participants per group for the primary endpoint postoperative morbidity according to comprehensive complication index (CCI) within 30 postoperative days. Secondary endpoints include anastomotic insufficiency, pulmonary complications, other intra- and postoperative outcome parameters such as estimated blood loss, operative time, length of stay, short-term oncologic endpoints, adherence to a standardized fast-track protocol, postoperative pain, and postoperative recovery (QoR-15). Quality of life (SF-36, CAT EORTC QLQ-C30, CAT EORTC QLQ-OES18) and oncological outcomes are evaluated with 60 months follow-up. MIVATE is the first RCT to compare OE with circular stapled anastomosis to total MIE with linear stapled anastomosis exclusively for intrathoracic anastomosis. The expertise-based approach limits bias due to heterogeneity of surgical expertise. The use of a dedicated fast-track protocol in both OE and MIE will shed light on the role of the access strategy alone in this setting. The findings of this study will serve to define which approach has the best perioperative outcome for patients requiring esophagectomy. German Clinical Trials Register DRKS00016773 . Registered on 18 February 2019.

Sections du résumé

BACKGROUND BACKGROUND
The only curative treatment for most esophageal cancers is radical esophagectomy. Minimally invasive esophagectomy (MIE) aims to reduce postoperative morbidity, but is not yet widely established. Linear stapled anastomosis is a promising technique for MIE because it is quite feasible even without robotic assistance. The aim of the present study is to compare total MIE with linear stapled anastomosis to open esophagectomy (OE) with circular stapled anastomosis with special regard to postoperative morbidity in an expertise-based randomized controlled trial (RCT).
METHODS/DESIGN METHODS
This superiority RCT compares MIE with linear stapled anastomosis (intervention) to OE with circular stapled anastomosis (control) for Ivor-Lewis esophagectomy. It was initiated in February 2019, and recruitment is expected to last for 3 years. For inclusion, patients must be 18 years of age or more with a resectable primary malignancy in the distal esophagus. Participants with tumor localizations above the azygos vein, metastasis, or infiltration into adjacent tissue will be excluded. In an expertise-based approach, the allocated treatment will only be carried out by the single most experienced surgeon of the surgical center for each respective technique. The sample size was calculated with 20 participants per group for the primary endpoint postoperative morbidity according to comprehensive complication index (CCI) within 30 postoperative days. Secondary endpoints include anastomotic insufficiency, pulmonary complications, other intra- and postoperative outcome parameters such as estimated blood loss, operative time, length of stay, short-term oncologic endpoints, adherence to a standardized fast-track protocol, postoperative pain, and postoperative recovery (QoR-15). Quality of life (SF-36, CAT EORTC QLQ-C30, CAT EORTC QLQ-OES18) and oncological outcomes are evaluated with 60 months follow-up.
DISCUSSION CONCLUSIONS
MIVATE is the first RCT to compare OE with circular stapled anastomosis to total MIE with linear stapled anastomosis exclusively for intrathoracic anastomosis. The expertise-based approach limits bias due to heterogeneity of surgical expertise. The use of a dedicated fast-track protocol in both OE and MIE will shed light on the role of the access strategy alone in this setting. The findings of this study will serve to define which approach has the best perioperative outcome for patients requiring esophagectomy.
TRIAL REGISTRATION BACKGROUND
German Clinical Trials Register DRKS00016773 . Registered on 18 February 2019.

Identifiants

pubmed: 33430937
doi: 10.1186/s13063-020-04966-z
pii: 10.1186/s13063-020-04966-z
pmc: PMC7798277
doi:

Types de publication

Clinical Trial Protocol Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

41

Références

Surg Obes Relat Dis. 2015 Nov-Dec;11(6):1233-6
pubmed: 25979205
J Am Coll Surg. 2014 Jun;218(6):1130-40
pubmed: 24698488
Eur J Cancer. 2018 Sep;100:8-16
pubmed: 29936066
World J Surg Oncol. 2016 Dec 8;14(1):304
pubmed: 27927246
Surg Endosc. 2016 Sep;30(9):3873-81
pubmed: 26659248
J Vis Surg. 2017 Sep 14;3:125
pubmed: 29078685
Rev Panam Salud Publica. 2015 Dec;38(6):506-14
pubmed: 27440100
Gut Liver. 2019 Mar 15;13(2):149-153
pubmed: 30419630
J Gastrointest Surg. 2012 Sep;16(9):1768-74
pubmed: 22777054
JAMA Surg. 2017 Aug 1;152(8):784-791
pubmed: 28467526
Anticancer Res. 2019 Feb;39(2):979-985
pubmed: 30711984
Surgery. 2017 Feb;161(2):365-372
pubmed: 27692778
Chirurg. 2020 Dec;91(Suppl 1):13-14
pubmed: 32179952
Health Technol Assess. 2016 Jun;20(48):1-68
pubmed: 27373720
Langenbecks Arch Surg. 2019 May;404(3):273-284
pubmed: 30824993
Surgery. 2017 Mar;161(3):584-591
pubmed: 28040257
Langenbecks Arch Surg. 2016 Sep;401(6):747-56
pubmed: 27401326
Dtsch Arztebl Int. 2018 Nov 23;115(47):793-800
pubmed: 30636674
Br J Surg. 2012 Nov;99(11):1547-53
pubmed: 23027071
Ann Surg. 2011 Jun;253(6):1111-7
pubmed: 21412146
Ann Surg. 2015 Jun;261(6):1114-23
pubmed: 25243545
N Engl J Med. 2013 Oct 10;369(15):1434-42
pubmed: 24106936
Ann Surg. 2013 Jul;258(1):1-7
pubmed: 23728278
Br J Surg. 2017 Jan;104(1):108-117
pubmed: 27763684
Ann Surg. 2014 Mar;259(3):413-31
pubmed: 24253135
Lancet. 2012 May 19;379(9829):1887-92
pubmed: 22552194
Ann Surg. 2019 Apr;269(4):621-630
pubmed: 30308612
Lancet Gastroenterol Hepatol. 2019 Mar;4(3):199-207
pubmed: 30685489
Ann Surg. 2004 Aug;240(2):205-13
pubmed: 15273542
Ann Surg. 2014 Aug;260(2):220-9
pubmed: 24743623
N Engl J Med. 2019 Jan 10;380(2):152-162
pubmed: 30625052
Lancet. 1986 Feb 8;1(8476):311-3
pubmed: 2868173
Ann Surg. 2014 Nov;260(5):757-62; discussion 762-3
pubmed: 25379846
J Thorac Cardiovasc Surg. 2018 Oct;156(4):1739-1745.e1
pubmed: 30033105
Surg Endosc. 2013 Apr;27(4):1346-52
pubmed: 23093242
Br J Surg. 2013 Jan;100(2):172-3
pubmed: 23180610
World J Gastroenterol. 2009 Jan 28;15(4):496-501
pubmed: 19152457
Ann Surg. 2015 Aug;262(2):286-94
pubmed: 25607756
Langenbecks Arch Surg. 2017 Sep;402(6):911-916
pubmed: 28689322
Ann Surg. 2017 Nov;266(5):814-821
pubmed: 28796646
J Thorac Dis. 2017 Sep;9(9):3005-3012
pubmed: 29221273
Ann Surg. 2017 Aug;266(2):232-236
pubmed: 28187044
Medicine (Baltimore). 2015 Aug;94(33):e1369
pubmed: 26287423

Auteurs

Felix Nickel (F)

Department of General, Visceral and Transplantation Surgery, Heidelberg University Hospital, Im Neuenheimer Feld 420, 69120, Heidelberg, Germany.

Pascal Probst (P)

Department of General, Visceral and Transplantation Surgery, Heidelberg University Hospital, Im Neuenheimer Feld 420, 69120, Heidelberg, Germany.

Alexander Studier-Fischer (A)

Department of General, Visceral and Transplantation Surgery, Heidelberg University Hospital, Im Neuenheimer Feld 420, 69120, Heidelberg, Germany.

Henrik Nienhüser (H)

Department of General, Visceral and Transplantation Surgery, Heidelberg University Hospital, Im Neuenheimer Feld 420, 69120, Heidelberg, Germany.

Jana Pauly (J)

Department of General, Visceral and Transplantation Surgery, Heidelberg University Hospital, Im Neuenheimer Feld 420, 69120, Heidelberg, Germany.

Karl-Friedrich Kowalewski (KF)

Department of General, Visceral and Transplantation Surgery, Heidelberg University Hospital, Im Neuenheimer Feld 420, 69120, Heidelberg, Germany.

Sebastian Weiterer (S)

Department of Anaesthesiology, Heidelberg University Hospital, Im Neuenheimer Feld 420, 69120, Heidelberg, Germany.

Philipp Knebel (P)

Department of General, Visceral and Transplantation Surgery, Heidelberg University Hospital, Im Neuenheimer Feld 420, 69120, Heidelberg, Germany.

Markus K Diener (MK)

Department of General, Visceral and Transplantation Surgery, Heidelberg University Hospital, Im Neuenheimer Feld 420, 69120, Heidelberg, Germany.

Markus A Weigand (MA)

Department of Anaesthesiology, Heidelberg University Hospital, Im Neuenheimer Feld 420, 69120, Heidelberg, Germany.

Markus W Büchler (MW)

Department of General, Visceral and Transplantation Surgery, Heidelberg University Hospital, Im Neuenheimer Feld 420, 69120, Heidelberg, Germany.

Thomas Schmidt (T)

Department of General, Visceral and Transplantation Surgery, Heidelberg University Hospital, Im Neuenheimer Feld 420, 69120, Heidelberg, Germany.

Beat P Müller-Stich (BP)

Department of General, Visceral and Transplantation Surgery, Heidelberg University Hospital, Im Neuenheimer Feld 420, 69120, Heidelberg, Germany. beat.mueller@med.uni-heidelberg.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH